Ceftolozane/Tazobactam Probability of Target Attainment in Patients With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia.

Autor: Gao W; Merck & Co., Inc., Rahway, New Jersey, USA., Patel YT; Cognigen Corporation, Simulations Plus Company, Buffalo, New Jersey, USA., Zhang Z; Merck & Co., Inc., Rahway, New Jersey, USA., Johnson MG; Merck & Co., Inc., Rahway, New Jersey, USA., Fiedler-Kelly J; Cognigen Corporation, Simulations Plus Company, Buffalo, New Jersey, USA., Bruno CJ; Merck & Co., Inc., Rahway, New Jersey, USA., Rhee EG; Merck & Co., Inc., Rahway, New Jersey, USA., Anda C; Merck & Co., Inc., Rahway, New Jersey, USA., Feng HP; Merck & Co., Inc., Rahway, New Jersey, USA.
Jazyk: angličtina
Zdroj: Journal of clinical pharmacology [J Clin Pharmacol] 2023 Mar; Vol. 63 (3), pp. 352-357. Date of Electronic Publication: 2022 Nov 22.
DOI: 10.1002/jcph.2165
Abstrakt: Probability of target attainment (PTA) analyses were conducted to support the recommended ceftolozane/tazobactam dosing regimens, adjusted for renal function, in patients with hospital-acquired/ventilator-associated bacterial pneumonia (HABP/VABP). Previously published population pharmacokinetic models describing the disposition of ceftolozane and tazobactam in plasma and epithelial lining fluid (ELF) in patients with HABP/VABP were used to simulate ceftolozane and tazobactam concentration-time profiles in plasma and ELF over the course of 14 days. The simulations were conducted for patients with normal renal function and for patients receiving adjusted doses for mild, moderate, and severe renal impairment. PTA was calculated using established pharmacokinetic/pharmacodynamic targets for ceftolozane and tazobactam. Across renal function groups, plasma PTA was 100% for ceftolozane and >99% for tazobactam; ELF PTA was >99% for ceftolozane and >87% for tazobactam. These results provided support for the currently recommended ceftolozane/tazobactam dosing regimens for HABP/VABP, which were efficacious and well tolerated in the Ceftolozane-Tazobactam Versus Meropenem for Treatment of Nosocomial Pneumonia (ASPECT-NP) trial.
(© 2022 Merck Sharp & Dohme Corp and The Authors. The Journal of Clinical Pharmacology published by Wiley Periodicals LLC on behalf of American College of Clinical Pharmacology.)
Databáze: MEDLINE
Externí odkaz: